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and 31% in women. In contrast, Wong et al,3 evaluating na-
tional data from Australia, reported an increase in age- and sex-
adjusted incidence from 1993 to 2010 from 215 to 251 cases per
100 000 person-years.
Our Medicare population differs significantly from the US
community-based sample evaluated by Yeh et al1 owing to
higher proportions of older and female patients. Moreover, un-
like other investigators studying Medicare patients (eg, Chen
et al4 and Wang et al5), we determined the cumulative inci-
dence of ACS, not just AMI, for nearly 2 decades. This study
illustrates the disproportionate reduction in the incidence of
unstable angina relative to AMI in the most recent decade. Our
study is limited, however, by our use of administrative data,
which are subject to appropriate coding, and our lack of clini-
cal data.
In conclusion, the declining incidence of ACS from 2002
to 2009 demonstrates that improvement in cardiovascular out-
comes extends to Medicare beneficiaries, probably reflecting
better implementation of preventive strategies. This paral-
lels a simultaneous reduction in US mortality rates associ-
ated with cardiovascular and coronary heart disease.6 How-
ever, our findings indicate that the AMI incidence among
Medicare patients is higher than community-based estimates
and has declined only modestly in nearly 2 decades, deserv-
ing additional attention. Importantly, the trend of declining ACS
incidence was driven primarily by a reduction in unstable an-
gina diagnoses, probably reflecting more frequent diagnosis
of AMI relative to unstable angina due to expanded use of more
sensitive cardiac biomarkers and changing definitions of AMI.
These observations have important clinical and economic im-
plications for this vulnerable patient population.
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Baseline Adherence to the Mediterranean Diet
and Major Cardiovascular Events: Prevención
con Dieta Mediterránea Trial
Lifestyle modification, particularly dietary changes, is the cor-
nerstone of population-based strategies for cardiovascular dis-
ease (CVD) prevention.1 Recently the Prevención con Dieta
Mediterránea (PREDIMED) study,2 a 5-year randomized pri-
mary prevention trial (isrctn.org Identifier: ISRCTN35739639),
showed a 30% reduction in incident CVD with Mediterranean
diet (MeDiet) intervention in comparison with a control diet.
At quarterly visits throughout the study, a validated 14-item
MeDiet screening tool (Table 1) was used to assess conformity
with this dietary pattern.3
Close monitoring of adherence to dietary instructions for
CVD prevention is difficult in the clinical setting. Short di-
etary assessment tools, such as the PREDIMED screener, are
desirable to identify individuals in need of dietary counsel-
ing. Given that there is little information on the association of
diet scores with disease outcomes in longitudinal studies, we
investigated whether the baseline 14-point MeDiet score was
related to incident CVD in the PREDIMED cohort.
Methods | Design. The PREDIMED study is a large random-
ized trial testing the effect of 2 MeDiets (supplemented with
either extra-virgin olive oil or nuts) compared with a control
diet (advice on a low-fat diet) on incident CVD in individuals
at high risk for but no CVD diagnosed at enrollment. The tri-
al’s design, objectives, and methods have been described.2 Par-
ticipants included 7447 men and women (mean age, 67 years)
with either diabetes mellitus or 3 or more cardiovascular risk
factors. The primary end point was an aggregate of myocar-
dial infarction, stroke, or cardiovascular death. This study was
approved by the institutional review board of Hospital Clinic,
Barcelona, Spain. Written informed consent was obtained from
all participants.
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Statistical Analysis. General linear modeling procedures were
used to compare baseline characteristics of participants by
score categories of the 14-point MeDiet screener. Multiple-
adjusted Cox proportional hazards regression models were fit-
ted to assess the association between the MeDiet score (or each
component) and the major end point. We also generated a
weighted MeDiet score to determine whether weighting each
score’s item modified the magnitude of the hazard ratios for
the association with the outcome.
Results | During a median follow-up of 4.8 years totaling 31 979
person-years, 288 participants sustained CVD events (139
strokes, 106 myocardial infarctions, and 87 cardiovascular
deaths). A 2-point increase in unweighted and weighted scores
was associated with 21% and 25% reductions in CVD events,
respectively, in fully adjusted models (Table 2). Associations
between MeDiet scores and CVD were weaker in women and
in the control group, but were strengthened by using weighted
scores. The proportional hazards assumption was tested (un-









All variablesb 7447 288 0.79 (0.70-0.89) 0.75 (0.67-0.84)
By sexb
Men 3165 171 0.73 (0.62-0.86) 0.72 (0.63-0.84)
Women 4282 117 0.90 (0.73-1.10) 0.83 (0.67-0.99)
By intervention armc
MeDiet with extra-virgin olive oil 2543 96 0.75 (0.60-0.93) 0.74 (0.61-0.89)
MeDiet with nuts 2454 83 0.67 (0.53-0.86) 0.70 (0.56-0.86)
Control diet 2450 109 0.90 (0.73-1.11) 0.81 (0.67-0.97)
By type of eventc
Myocardial infarction 7447 106 0.73 (0.59-0.89) 0.68 (0.57-0.81)
Stroke 7447 139 0.82 (0.68-0.98) 0.79 (0.67-0.92)
Cardiovascular death 7447 87 0.72 (0.58-0.90) 0.69 (0.57-0.85)
Abbreviations: CVD, cardiovascular
disease; HR, hazard ratio;
MeDiet, Mediterranean diet.
a Myocardial infarction, stroke, or
cardiovascular death.
b Adjusted for age, smoking, diabetes
mellitus, hypertension,
dyslipidemia, body mass index,
family history of premature
coronary heart disease, recruiting
center, intervention group,
leisure-time physical activity, and
educational level.
c Additionally adjusted for sex.






1. Do you use olive oil as the principal source of fat for cooking? Yes 0.75 (0.52-1.08) 0.77 (0.54-1.16)
2. How much olive oil do you consume per day, including that used
in frying, salads, meals eaten away from home, etc?
≥54 ge 0.82 (0.63-1.06) 0.85 (0.65-1.10)
3. How many servings of vegetables do you consume per day? (count garnish and side servings
as ½ point; a full serving is 200 g)
≥2 0.62 (0.52-0.85) 0.65 (0.51-0.83)
4. How many pieces of fruit, including fresh-squeezed juice, do you consume per day? ≥3 0.94 (0.74-1.18) 0.97 (0.77-1.22)
5. How many servings of red meat, hamburger, or sausages do you consume per day?
(a full serving is 100-150 g)
<1 0.75 (0.55-1.03) 0.77 (0.57-1.05)
6. How many 12-g servings of butter, margarine, or cream do you consume per day? <1 0.71 (0.50-1.01) 0.73 (0.52-1.04)
7. How many carbonated and/or sugar-sweetened beverages do you consume per day? <1 0.97 (0.67-1.39) 0.99 (0.69-1.42)
8. Do you drink wine? How much do you consume per week? ≥700 mLf 0.75 (0.58-0.98) 0.81 (0.62-1.06)
9. How many 150-g servings of legumes do you consume per week? ≥3 1.19 (0.93-1.54) 1.21 (0.93-1.59)
10. How many servings of fish/seafood do you consume per week? (100-150 g of fish,
4-5 pieces or 200 g of seafood)
≥3 0.99 (0.78-1.24) 1.00 (0.79-1.28)
11. How many times do you consume commercial (not homemade) pastry, such as cookies
or cake, per week?
<2 0.94 (0.73-1.20) 0.92 (0.72-1.18)
12. How many times do you consume nuts per week? (1 serving = 30 g) ≥3 0.72 (0.56-0.93) 0.75 (0.58-0.97)
13. Do you prefer to eat chicken, turkey, or rabbit instead of beef, pork, hamburgers,
or sausages?
Yes 0.86 (0.67-1.09) 0.85 (0.66-1.08)
14. How many times per week do you consume boiled vegetables, pasta, rice,
or other dishes with a sauce of tomato, garlic, onion, or
leeks sautéed in olive oil?
≥2 0.80 (0.63-1.01) 0.80 (0.63-1.02)
Abbreviation: HR, hazard ratio.
a Cardiovascular events included death, myocardial infarction, or stroke.
b If the criteria listed were met, 1 point was assigned; if these were not met,
0 was recorded.
c Adjusted for sex and age.
d Additionally adjusted for smoking, leisure-time physical activity, diabetes
mellitus, hypertension, hypercholesterolemia, educational level, intervention
group, recruiting center, weight, and family history of premature coronary
heart disease.
e Fifty-four grams is 4 tbsp.
f One hundred milliliters is 1 c.
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weighted P > .99; weighted P = .74). Among individual score
components, only increased consumption of vegetables and
nuts were related to reduced CVD events (Table 1).
Discussion | As assessed by a short 14-item screener, baseline
adherence to the MeDiet in the PREDIMED trial showed an in-
verse association with incident CVD, independent of lifestyle
and classical risk factors. Our findings further document the
beneficial effect of the MeDiet on CVD in the PREDIMED trial2
and support the 14-item MeDiet screener as a useful tool to
identify individuals needing dietary counseling. It is not sur-
prising that the overall score showed an inverse association
with CVD and that most individual score components did not
show an inverse association. The combination of foods in an
overall healthy dietary pattern is likely to provide stronger pro-
tection because this approach captures potential interactions
and synergies between different foods and nutrients, reflect-
ing the effect of the whole diet.4 In the present study, a 2-point
increase in the 14-point MeDiet score was associated with a 21%
reduction in CVD risk. Weighting the strength of each score
component increased the magnitude of the association. The
extent of the MeDiet’s protective effect estimated by the
screener was similar or greater than that reported for MeDiet
scores derived from complex, time-consuming food fre-
quency questionnaires.5,6 This screener is thus a useful, simple
tool to identify and educate individuals who would benefit
most from dietary intervention to reduce future CVD risk.
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